share_log

Allogene Therapeutics Analyst Ratings

Allogene Therapeutics Analyst Ratings

Allogene Therapeutic
Benzinga ·  2023/08/07 06:21
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/07/2023 401.09% HC Wainwright & Co. → $23 Reiterates Buy → Buy
08/03/2023 510.02% Oppenheimer → $28 Reiterates Outperform → Outperform
08/03/2023 226.8% EF Hutton → $15 Reiterates Buy → Buy
07/12/2023 292.16% Truist Securities $20 → $18 Maintains Buy
06/26/2023 510.02% Oppenheimer → $28 Assumes → Outperform
06/20/2023 401.09% HC Wainwright & Co. → $23 Reiterates Buy → Buy
06/16/2023 662.53% Canaccord Genuity → $35 Reiterates Buy → Buy
06/05/2023 226.8% JMP Securities → $15 Reiterates → Market Outperform
06/05/2023 226.8% EF Hutton → $15 Reiterates Buy → Buy
05/26/2023 226.8% EF Hutton → $15 Reiterates Buy → Buy
05/05/2023 226.8% JMP Securities $19 → $15 Maintains Outperform
05/05/2023 401.09% HC Wainwright & Co. → $23 Reiterates → Buy
05/04/2023 63.4% Stifel $8 → $7.5 Maintains Hold
05/04/2023 226.8% RBC Capital → $15 Reiterates → Outperform
04/20/2023 401.09% HC Wainwright & Co. → $23 Reiterates → Buy
04/18/2023 313.94% JMP Securities → $19 Reiterates → Market Outperform
04/17/2023 226.8% EF Hutton → $15 Maintains Buy
04/04/2023 401.09% HC Wainwright & Co. $29 → $23 Maintains Buy
03/21/2023 30.72% Bernstein → $6 Initiates Coverage On → Market Perform
03/02/2023 575.38% Goldman Sachs $35 → $31 Maintains Buy
03/02/2023 313.94% JMP Securities $23 → $19 Maintains Market Perform
03/01/2023 379.3% RBC Capital $32 → $22 Maintains Outperform
03/01/2023 510.02% Oppenheimer $32 → $28 Maintains Outperform
03/01/2023 575.38% Goldman Sachs $35 → $31 Maintains Buy
03/01/2023 226.8% EF Hutton → $15 Reiterates → Buy
01/24/2023 139.65% JP Morgan $20 → $11 Upgrades Neutral → Overweight
01/06/2023 161.44% Baird → $12 Upgrades Neutral → Outperform
01/05/2023 226.8% EF Hutton → $15 Initiates Coverage On → Buy
12/12/2022 96.08% B of A Securities → $9 Downgrades Buy → Underperform
11/21/2022 531.81% HC Wainwright & Co. $43 → $29 Maintains Buy
09/22/2022 292.16% B. Riley Securities $21 → $18 Maintains Buy
08/10/2022 662.53% Oppenheimer $40 → $35 Maintains Outperform
08/10/2022 597.17% RBC Capital $35 → $32 Maintains Outperform
08/10/2022 — Raymond James Downgrades Outperform → Market Perform
07/15/2022 597.17% Goldman Sachs $9 → $32 Upgrades Neutral → Buy
06/03/2022 139.65% Baird → $11 Initiates Coverage On → Neutral
05/24/2022 96.08% Goldman Sachs $12 → $9 Maintains Neutral
05/05/2022 183.22% Raymond James $36 → $13 Maintains Outperform
03/07/2022 161.44% Goldman Sachs $20 → $12 Maintains Neutral
12/14/2021 662.53% RBC Capital $45 → $35 Maintains Outperform
10/12/2021 488.24% JMP Securities $53 → $27 Maintains Market Outperform
10/08/2021 — Stifel Downgrades Buy → Hold
10/08/2021 880.39% RBC Capital $55 → $45 Maintains Outperform
10/08/2021 335.73% Goldman Sachs $71 → $20 Downgrades Buy → Neutral
09/24/2021 684.31% Raymond James → $36 Upgrades Market Perform → Outperform
09/23/2021 684.31% Raymond James → $36 Upgrades Market Perform → Outperform
05/20/2021 793.25% Truist Securities $34 → $41 Upgrades Hold → Buy
05/14/2021 1032.9% B. Riley Securities → $52 Initiates Coverage On → Buy
03/01/2021 836.82% HC Wainwright & Co. $40 → $43 Maintains Buy
01/26/2021 836.82% Stifel $33 → $43 Upgrades Hold → Buy
12/10/2020 771.46% HC Wainwright & Co. → $40 Assumes → Buy
10/23/2020 1098.26% RBC Capital → $55 Initiates Coverage On → Outperform
06/12/2020 967.54% HC Wainwright & Co. $55 → $49 Maintains Buy
06/01/2020 1098.26% Oppenheimer $50 → $55 Maintains Outperform
06/01/2020 — Raymond James Downgrades Outperform → Market Perform
05/19/2020 1207.19% Roth Capital → $60 Upgrades Neutral → Buy
05/15/2020 — Guggenheim Upgrades Neutral → Buy
05/14/2020 858.61% Canaccord Genuity $36 → $44 Maintains Buy
05/14/2020 989.32% Oppenheimer $44 → $50 Maintains Outperform
05/14/2020 815.03% HC Wainwright & Co. $35 → $42 Reiterates → Buy
05/14/2020 597.17% SunTrust Robinson Humphrey $29 → $32 Downgrades Buy → Hold
04/13/2020 531.81% SunTrust Robinson Humphrey → $29 Initiates Coverage On → Buy
02/24/2020 488.24% Berenberg → $27 Initiates Coverage On → Hold
12/18/2019 706.1% JMP Securities → $37 Initiates Coverage On → Market Outperform
11/04/2019 684.31% Canaccord Genuity → $36 Initiates Coverage On → Buy
08/09/2019 706.1% BTIG → $37 Initiates Coverage On → Buy
06/05/2019 466.45% Roth Capital → $26 Initiates Coverage On → Neutral
05/31/2019 — Guggenheim Initiates Coverage On → Neutral
05/23/2019 488.24% Stifel → $27 Initiates Coverage On → Hold
05/03/2019 880.39% Oppenheimer → $45 Initiates Coverage On → Outperform
03/29/2019 989.32% Piper Sandler → $50 Initiates Coverage On → Overweight
03/15/2019 771.46% Raymond James → $40 Initiates Coverage On → Outperform
03/14/2019 — William Blair Initiates Coverage On → Outperform
11/05/2018 — Cowen & Co. Initiates Coverage On → Outperform
11/05/2018 531.81% JP Morgan → $29 Initiates Coverage On → Neutral
11/05/2018 575.38% Jefferies → $31 Initiates Coverage On → Buy
11/05/2018 793.25% Goldman Sachs → $41 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變化 評級變化 上一次/當前評級
08/07/2023 401.09% HC Wainwright公司 →$23 重申 購買→購買
08/03/2023 510.02% 奧本海默 →$28 重申 跑贏→跑贏大盤
08/03/2023 226.8% EF Hutton →$15 重申 購買→購買
07/12/2023 292.16% Truist證券 $20→$18 維護 買
2023/06/26 510.02% 奧本海默 →$28 假設 →跑贏大盤
06/20/2023 401.09% HC Wainwright公司 →$23 重申 購買→購買
06/16/2023 662.53% 卡納科特·格納奇 →$35 重申 購買→購買
06/05/2023 226.8% JMP證券 →$15 重申 →市場跑贏大盤
06/05/2023 226.8% EF Hutton →$15 重申 購買→購買
2023年05月26日 226.8% EF Hutton →$15 重申 購買→購買
05/05/2023 226.8% JMP證券 $19→$15 維護 跑贏大盤
05/05/2023 401.09% HC Wainwright公司 →$23 重申 →購買
05/04/2023 63.4% Stifel $8→$7.5 維護 保持
05/04/2023 226.8% 加拿大皇家銀行資本 →$15 重申 →跑贏大盤
04/20/2023 401.09% HC Wainwright公司 →$23 重申 →購買
04/18/2023 313.94% JMP證券 →$19 重申 →市場跑贏大盤
04/17/2023 226.8% EF Hutton →$15 維護 買
04/04/2023 401.09% HC Wainwright公司 $29→$23 維護 買
03/21/2023 30.72% 伯恩斯坦 →$6 開始承保 →市場表現
03/02/2023 575.38% 高盛 $35→$31 維護 買
03/02/2023 313.94% JMP證券 $23→$19 維護 市場表現
03/01/2023 379.3% 加拿大皇家銀行資本 $32→$22 維護 跑贏大盤
03/01/2023 510.02% 奧本海默 $32→$28 維護 跑贏大盤
03/01/2023 575.38% 高盛 $35→$31 維護 買
03/01/2023 226.8% EF Hutton →$15 重申 →購買
01/24/2023 139.65% 摩根大通 $20→$11 升級 中性→超重
01/06/2023 161.44% 貝爾德 →$12 升級 中性→表現優異
01/05/2023 226.8% EF Hutton →$15 開始承保 →購買
2022年12月12日 96.08% B of A證券 →$9 評級下調 購買表現不佳的→
2022年11月21日 531.81% HC Wainwright公司 $43→$29 維護 買
09/22/2022 292.16% B.萊利證券 $21→$18 維護 買
2022年08月10日 662.53% 奧本海默 $40→$35 維護 跑贏大盤
2022年08月10日 597.17% 加拿大皇家銀行資本 $35→$32 維護 跑贏大盤
2022年08月10日 - 雷蒙德·詹姆斯 評級下調 跑贏→市場表現
07/15/2022 597.17% 高盛 $9→$32 升級 中性→購買
06/03/2022 139.65% 貝爾德 →$11 開始承保 →中性
2022年05月24日 96.08% 高盛 $12→$9 維護 中性
05/05/2022 183.22% 雷蒙德·詹姆斯 $36→$13 維護 跑贏大盤
03/07/2022 161.44% 高盛 $20→$12 維護 中性
2021年12月14日 662.53% 加拿大皇家銀行資本 $45→$35 維護 跑贏大盤
10/12/2021 488.24% JMP證券 $53→$27 維護 市場表現強於大盤
10/08/2021 - Stifel 評級下調 購買→Hold
10/08/2021 880.39% 加拿大皇家銀行資本 $55→$45 維護 跑贏大盤
10/08/2021 335.73% 高盛 $71→$20 評級下調 購買→中性
09/24/2021 684.31% 雷蒙德·詹姆斯 →$36 升級 市場表現優於→
09/23/2021 684.31% 雷蒙德·詹姆斯 →$36 升級 市場表現優於→
05/20/2021 793.25% Truist證券 $34→$41 升級 持有→購買
2021/05/14 1032.9% B.萊利證券 →$52 開始承保 →購買
03/01/2021 836.82% HC Wainwright公司 $40→$43 維護 買
2021/01/26 836.82% Stifel $33→$43 升級 持有→購買
12/10/2020 771.46% HC Wainwright公司 →$40 假設 →購買
10/23/2020 1098.26% 加拿大皇家銀行資本 →$55 開始承保 →跑贏大盤
2020/06/12 967.54% HC Wainwright公司 $55→$49 維護 買
06/01/2020 1098.26% 奧本海默 $50→$55 維護 跑贏大盤
06/01/2020 - 雷蒙德·詹姆斯 評級下調 跑贏→市場表現
2020/05/19 1207.19% 羅斯資本 →$60 升級 中性→購買
2020/05/15 - 古根海姆 升級 中性→購買
2020/05/14 858.61% 卡納科特·格納奇 $36→$44 維護 買
2020/05/14 989.32% 奧本海默 $44→$50 維護 跑贏大盤
2020/05/14 815.03% HC Wainwright公司 $35→$42 重申 →購買
2020/05/14 597.17% SunTrust Robinson Humphrey $29→$32 評級下調 購買→Hold
04/13/2020 531.81% SunTrust Robinson Humphrey →$29 開始承保 →購買
02/24/2020 488.24% 貝倫伯格 →$27 開始承保 →保留
2019年12月18日 706.1% JMP證券 →$37 開始承保 →市場跑贏大盤
2019/11/04 684.31% 卡納科特·格納奇 →$36 開始承保 →購買
2019年08月09日 706.1% BTIG →$37 開始承保 →購買
2019年05月06日 466.45% 羅斯資本 →$26 開始承保 →中性
2019年05月31日 - 古根海姆 開始承保 →中性
2019年05月23日 488.24% Stifel →$27 開始承保 →保留
2019年05月03日 880.39% 奧本海默 →$45 開始承保 →跑贏大盤
2019/03/29 989.32% 派珀·桑德勒 →$50 開始承保 →超重
2019年03月15日 771.46% 雷蒙德·詹姆斯 →$40 開始承保 →跑贏大盤
2019/03/14 - 威廉·布萊爾 開始承保 →跑贏大盤
2018年11月05日 - 考恩公司 開始承保 →跑贏大盤
2018年11月05日 531.81% 摩根大通 →$29 開始承保 →中性
2018年11月05日 575.38% 傑富瑞 →$31 開始承保 →購買
2018年11月05日 793.25% 高盛 →$41 開始承保 →購買

What is the target price for Allogene Therapeutics (ALLO)?

同種異體基因治療(ALLO)的目標價格是多少？

The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $23.00 expecting ALLO to rise to within 12 months (a possible 401.09% upside). 34 analyst firms have reported ratings in the last year.

同種異體基因治療公司(納斯達克：ALLO)的最新目標價是由HC Wainwright&Co.於2023年8月7日報道的。這家分析公司將目標價定為2300美元，預計Allo將在12個月內上漲至(可能上漲401.09%)。去年有34家分析公司公佈了評級。

What is the most recent analyst rating for Allogene Therapeutics (ALLO)?

同種異體基因治療公司(Allo)的最新分析師評級是多少？

The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by HC Wainwright & Co., and Allogene Therapeutics reiterated their buy rating.

納斯達克(代碼：ALLO)的最新分析師評級是由HC Wainwright&Co.提供的，Allgene治療公司重申了他們的買入評級。

When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?

異基因治療公司(Allo)的下一次分析師評級將於何時發佈或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.

分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與異種基因治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。異基因治療公司的上一次評級是在2023年8月7日提交的，所以你應該預計下一次評級將在2024年8月7日左右的某個時候提供。

Is the Analyst Rating Allogene Therapeutics (ALLO) correct?

分析師對同種異體基因治療公司(Allo)的評級正確嗎？

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a reiterated with a price target of $0.00 to $23.00. The current price Allogene Therapeutics (ALLO) is trading at is $4.59, which is within the analyst's predicted range.

雖然評級是主觀的，並將發生變化，但最新的異基因治療(Allo)評級被重申，目標價在0.00美元至23.00美元之間。異基因治療公司(Allo)目前的交易價格為4.59美元，在分析師的預測範圍內。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論